Perioperative remedial antiviral therapy in hepatitis B virus-related hepatocellular carcinoma resection: How to achieve a better outcome

Figure 1 Comparison of overall survival between the two groups.

Figure 2 Comparison of disease-free survival between the two groups.

Figure 3 Kaplan–Meier analysis of survival between the subgroups separated by different levels of hepatitis B virus-DNA. A: The difference between overall survival (OS) in the perioperative antiviral therapy group; B: The difference between disease-free survival (DFS) in the perioperative antiviral therapy group; C: The difference between OS in the long-term antiviral therapy group; D: The difference between DFS in the long-term antiviral therapy group. HBV: Hepatitis B virus.

Figure 4 Kaplan–Meier analysis of patient outcomes in subgroups based on the different types of surgery performed. A: The difference between overall survival (OS) in two groups received type II, III hepatectomy; B: The difference between OS in two groups received type I hepatectomy; C: The difference between disease-free survival (DFS) in two groups received type I hepatectomy; D: The difference between DFS in two groups received type II, III hepatectomy.